The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
AimThe efficacy and safety of simeprevir in combination with peginterferon‐α‐2b and ribavirin (PEG IFN‐α‐2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment‐naïve or had previously received interferon (IFN)‐based therapy.
MethodsCONCERTO‐4 (NCT01366638) was an open‐label, non‐comparative, multicenter study of once‐daily simeprevir (TMC435) 100...
In a Japanese Phase II study, the hepatitis C virus NS3/4A protease inhibitor simeprevir demonstrated potent antiviral activity and significantly improved sustained virologic response rates when added to peginterferon α-2a/ribavirin in treatment-naïve patients infected with hepatitis C virus genotype 1.CONCERTO-1 was a Phase III, randomized, double-blind, placebo-controlled trial. Treatment-naïve...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.